Pancreatic Cancer Breakthrough: New Daily Pill Doubles Survival Time

A new once-daily targeted therapy, daraxonrasib, has nearly doubled survival in patients with advanced pancreatic cancer in a landmark Phase 3 trial. Experts are calling it one of the most significant...